Sharon Barr, a molecular biologist and experienced pharma executive, has been appointed head of biopharmaceuticals R&D at AstraZeneca Plc, effective 1 August. She succeeds Mene Pangalos, who is retiring. Dr Barr will be responsible for discovery through to late-stage development across the company’s cardiovascular, renal and metabolism, and respiratory and immunology divisions, and join Astra Zeneca’s senior executive team. She has been head of research and product development at Alexion Pharmaceuticals since 2013. Alexion was acquired by AstraZeneca in 2021. Dr Barr received a PhD from New York University and completed a postdoctoral fellowship on DNA damage and repair at Stanford University, US.
AstraZeneca announced the appointment on 28 July 2023.
Copyright 2023 Evernow Publishing Ltd